These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 10780184)
1. Advances in the approach to acute coronary syndromes. Kong DF; Blazing MA; O'Connor CM Hosp Pract (1995); 2000 Apr; 35(4):61-4, 67-70, 73-4 passim. PubMed ID: 10780184 [TBL] [Abstract][Full Text] [Related]
2. Advances in post stenting medication protocol. Morice MC J Invasive Cardiol; 1995; 7 Suppl A():32A-35A. PubMed ID: 10155114 [No Abstract] [Full Text] [Related]
3. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423 [TBL] [Abstract][Full Text] [Related]
4. Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations. Brener SJ Cleve Clin J Med; 2000 Jan; 67(1):59-65. PubMed ID: 10645678 [TBL] [Abstract][Full Text] [Related]
5. Impact of new pharmacologic agents in the treatment of acute thrombotic syndromes. Stone GW Am J Cardiol; 1999 May; 83(9A):16E-20E. PubMed ID: 10357577 [No Abstract] [Full Text] [Related]
6. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts following percutaneous transluminal coronary angioplasty. Stein PD; Dalen JE; Goldman S; Schwartz L; Turpie AG; Théroux P Chest; 1992 Oct; 102(4 Suppl):508S-515S. PubMed ID: 1395831 [No Abstract] [Full Text] [Related]
7. Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical treatment of unstable coronary artery disease. Verheugt FW Haemostasis; 2000; 30 Suppl 2():122-7; discussion 106-7. PubMed ID: 11251355 [TBL] [Abstract][Full Text] [Related]
11. Contemporary view of the acute coronary syndromes. Moustapha A; Anderson HV J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619 [No Abstract] [Full Text] [Related]
12. Times they are a-changin. King SB JACC Cardiovasc Interv; 2012 Mar; 5(3):364-5. PubMed ID: 22440508 [No Abstract] [Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Lincoff AM; Califf RM; Topol EJ J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948 [TBL] [Abstract][Full Text] [Related]
14. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Fox KA; Goodman SG; Anderson FA; Granger CB; Moscucci M; Flather MD; Spencer F; Budaj A; Dabbous OH; Gore JM; Eur Heart J; 2003 Aug; 24(15):1414-24. PubMed ID: 12909070 [TBL] [Abstract][Full Text] [Related]
19. Use of evidence-based management for acute coronary syndrome. Tang E; Wong CK; Wilkins G; Herbison P; Williams M; Kay P; Restieaux N N Z Med J; 2005 Oct; 118(1223):U1678. PubMed ID: 16224502 [TBL] [Abstract][Full Text] [Related]
20. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both? Silva MA; Donovan JL; Gandhi PJ; Volturo GA Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]